Risa B Weisberg1, Courtney Beard, Ethan Moitra, Ingrid Dyck, Martin B Keller. 1. Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island; Department of Family Medicine, Alpert Medical School of Brown University, Providence, Rhode Island.
Abstract
BACKGROUND: We examined the adequacy of pharmacotherapy and psychotherapy received by primary care patients with anxiety disorders over up to 5 years of follow-up. METHOD: Five hundred thirty-four primary care patients at 15 US sites, who screened positive for anxiety symptoms, were assessed for anxiety disorders. Those meeting anxiety disorder criteria were offered participation and interviewed again at six and 12 months postintake, and yearly thereafter for up to 5 years. We utilized existing definitions of appropriate pharmacotherapy and created definitions of potentially adequate psychotherapy/cognitive-behavioral therapy (CBT). RESULTS: At intake, of 534 primary care participants with anxiety disorders, 19% reported receiving appropriate pharmacotherapy and 14% potentially adequate CBT. Overall, 28% of participants reported receiving potentially adequate anxiety treatment, whether pharmacotherapy, psychotherapy, or both. Over up to five years of follow-up, appropriate pharmacotherapy was received by 60% and potentially adequate CBT by 36% of the sample. Examined together, 69% of participants received any potentially adequate treatment during the follow-up period. Over the course of follow-up, primary care patients with MDD, panic disorder with agoraphobia, and with medicaid/medicare were more likely to receive appropriate anxiety treatment. Ethnic minority members were less likely to receive potentially adequate care. CONCLUSIONS: Potentially adequate anxiety treatment was rarely received by primary care patients with anxiety disorders at intake. Encouragingly, rates improved over the course of the study. However, potentially adequate CBT remained much less utilized than pharmacotherapy and racial-ethnic minority members were less likely to received care, suggesting much room for improved dissemination of quality treatment.
BACKGROUND: We examined the adequacy of pharmacotherapy and psychotherapy received by primary care patients with anxiety disorders over up to 5 years of follow-up. METHOD: Five hundred thirty-four primary care patients at 15 US sites, who screened positive for anxiety symptoms, were assessed for anxiety disorders. Those meeting anxiety disorder criteria were offered participation and interviewed again at six and 12 months postintake, and yearly thereafter for up to 5 years. We utilized existing definitions of appropriate pharmacotherapy and created definitions of potentially adequate psychotherapy/cognitive-behavioral therapy (CBT). RESULTS: At intake, of 534 primary care participants with anxiety disorders, 19% reported receiving appropriate pharmacotherapy and 14% potentially adequate CBT. Overall, 28% of participants reported receiving potentially adequate anxiety treatment, whether pharmacotherapy, psychotherapy, or both. Over up to five years of follow-up, appropriate pharmacotherapy was received by 60% and potentially adequate CBT by 36% of the sample. Examined together, 69% of participants received any potentially adequate treatment during the follow-up period. Over the course of follow-up, primary care patients with MDD, panic disorder with agoraphobia, and with medicaid/medicare were more likely to receive appropriate anxiety treatment. Ethnic minority members were less likely to receive potentially adequate care. CONCLUSIONS: Potentially adequate anxiety treatment was rarely received by primary care patients with anxiety disorders at intake. Encouragingly, rates improved over the course of the study. However, potentially adequate CBT remained much less utilized than pharmacotherapy and racial-ethnic minority members were less likely to received care, suggesting much room for improved dissemination of quality treatment.
Authors: G Steketee; J C Perry; R M Goisman; M G Warshaw; A O Massion; L G Peterson; L Langford; N Weinshenker; I G Farreras; M B Keller Journal: J Psychother Pract Res Date: 1997
Authors: Murray B Stein; Peter P Roy-Byrne; Michelle G Craske; Laura Campbell-Sills; Ariel J Lang; Daniella Golinelli; Raphael D Rose; Alexander Bystritsky; Greer Sullivan; Cathy D Sherbourne Journal: J Clin Psychiatry Date: 2011-02-22 Impact factor: 4.384
Authors: M Ansseau; M Dierick; F Buntinkx; P Cnockaert; J De Smedt; M Van Den Haute; D Vander Mijnsbrugge Journal: J Affect Disord Date: 2004-01 Impact factor: 4.839
Authors: Risa B Weisberg; Steven E Bruce; Jason T Machan; Ronald C Kessler; Larry Culpepper; Martin B Keller Journal: Psychiatr Serv Date: 2002-07 Impact factor: 3.084
Authors: Carlos Blanco; Franklin R Schneier; Andrew Schmidt; Carmen-Rosa Blanco-Jerez; Randall D Marshall; Arturo Sánchez-Lacay; Michael R Liebowitz Journal: Depress Anxiety Date: 2003 Impact factor: 6.505
Authors: Greta A Bushnell; Scott N Compton; Stacie B Dusetzina; Bradley N Gaynes; M Alan Brookhart; John T Walkup; Moira A Rynn; Til Stürmer Journal: J Clin Psychiatry Date: 2018 Jan/Feb Impact factor: 4.384